Aurobindo Pharma is likely to remain in focus after its wholly owned subsidiary, CuraTeQ Biologics, secured Good Manufacturing Practice (GMP) approval from Brazil's National Health Surveillance Agency (ANVISA) for its biosimilars manufacturing facility in Hyderabad. The approval follows a successful GMP inspection conducted from May 11 to May 15, 2026, covering the production of biological APIs and sterile products. The inspection evaluated four biosimilar products and assessed the company's mammalian and microbial drug substance manufacturing facilities, prefilled syringe and vial filling units, packaging and labelling operations, as well as quality control testing and product release laboratories. The Hyderabad facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO), further strengthening its global regulatory credentials. On the stock performance front, Aurobindo Pharma hit a 52-week high of Rs 1,636.00 on July 3, 2026, and a 52-week low of Rs 1,017.00 on September 2, 2025. The stock is currently trading 3.4 percent below its 52-week high and 55.4 percent above its 52-week low. The company's market capitalisation stands at Rs 91,792.79 crore.

#StockInNews

478 likes·59 comments